Long-term impact of adult WHO grade II or III gliomas on health-related quality of life: A systematic review.
adult
glioma
health-related quality of life
long-term
survivorship
Journal
Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
entrez:
28
1
2022
pubmed:
29
1
2022
medline:
29
1
2022
Statut:
epublish
Résumé
Glioma diagnosis can be devastating and result in a range of symptoms. Relatively little is known about the long-term health-related quality of life (HRQOL) challenges faced by these patients. Establishing the impact of diagnosis on HRQOL could help positively tailor clinical decision making regarding patient support and treatment. The aim of this review is to identify the long-term HRQOL issues reported at least 2 years following diagnosis of WHO grade II/III glioma. Systematic literature searches were carried out using Medline, EMBASE, CINAHL, PsycINFO, and Web of Science Core Collection. Searches were designed to identify patient self-reports on HRQOL aspects defined as physical, mental, or social issues. Quality assessment was conducted using the Mixed Methods Appraisal Tool (MMAT). Narrative synthesis was used to collate findings. The search returned 8923 articles. Two hundred seventy-eight titles remained after title and abstract screening, with 21 full-text articles included in the final analysis. The majority of studies used quantitative methods, with 3 articles reporting mixed methodology. Negative emotional/psychological/cognitive changes were the most commonly reported. Physical complaints included fatigue, seizures, and restricted daily activity. Social challenges included strained social relationships and financial problems. Patient coping strategies were suggested to influence patient's survival quality. The consequences of a glioma diagnosis and treatment can have substantial implications for patients' long-term HRQOL and daily functioning. Findings from this review lay the groundwork for efforts to improve patient HRQOL in long-term survivorship.
Sections du résumé
BACKGROUND
BACKGROUND
Glioma diagnosis can be devastating and result in a range of symptoms. Relatively little is known about the long-term health-related quality of life (HRQOL) challenges faced by these patients. Establishing the impact of diagnosis on HRQOL could help positively tailor clinical decision making regarding patient support and treatment. The aim of this review is to identify the long-term HRQOL issues reported at least 2 years following diagnosis of WHO grade II/III glioma.
METHOD
METHODS
Systematic literature searches were carried out using Medline, EMBASE, CINAHL, PsycINFO, and Web of Science Core Collection. Searches were designed to identify patient self-reports on HRQOL aspects defined as physical, mental, or social issues. Quality assessment was conducted using the Mixed Methods Appraisal Tool (MMAT). Narrative synthesis was used to collate findings.
RESULTS
RESULTS
The search returned 8923 articles. Two hundred seventy-eight titles remained after title and abstract screening, with 21 full-text articles included in the final analysis. The majority of studies used quantitative methods, with 3 articles reporting mixed methodology. Negative emotional/psychological/cognitive changes were the most commonly reported. Physical complaints included fatigue, seizures, and restricted daily activity. Social challenges included strained social relationships and financial problems. Patient coping strategies were suggested to influence patient's survival quality.
CONCLUSION
CONCLUSIONS
The consequences of a glioma diagnosis and treatment can have substantial implications for patients' long-term HRQOL and daily functioning. Findings from this review lay the groundwork for efforts to improve patient HRQOL in long-term survivorship.
Identifiants
pubmed: 35087674
doi: 10.1093/nop/npab062
pii: npab062
pmc: PMC8789291
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
3-17Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
Neuro Oncol. 2016 Mar;18(3):435-44
pubmed: 26385615
Ann Neurol. 1994 Jul;36(1):48-54
pubmed: 8024261
J Clin Neurosci. 2014 Aug;21(8):1304-9
pubmed: 24798909
Lancet Oncol. 2016 Nov;17(11):1533-1542
pubmed: 27686943
J Neurooncol. 2014 Jan;116(1):161-8
pubmed: 24162809
J Neurol Neurosurg Psychiatry. 2000 Jul;69(1):67-73
pubmed: 10864606
Qual Life Res. 2019 Nov;28(11):3107-3116
pubmed: 31230167
Int J Surg. 2021 Apr;88:105906
pubmed: 33789826
Neuro Oncol. 2000 Oct;2(4):221-8
pubmed: 11265231
World Neurosurg. 2017 Jul;103:799-808.e9
pubmed: 28411105
J Neurol Neurosurg Psychiatry. 1992 May;55(5):372-6
pubmed: 1602310
Front Neurol. 2018 Sep 11;9:763
pubmed: 30254605
Cancers (Basel). 2021 Mar 13;13(6):
pubmed: 33805663
J Clin Oncol. 2007 Dec 20;25(36):5723-30
pubmed: 18089866
Support Care Cancer. 2016 Dec;24(12):4939-4949
pubmed: 27432402
J Neurooncol. 2020 Apr;147(2):397-404
pubmed: 32096067
J Neurooncol. 2018 Mar;137(1):191-203
pubmed: 29236238
Psychother Psychosom. 2015;84(3):167-76
pubmed: 25831962
J Clin Oncol. 2011 Nov 20;29(33):4430-5
pubmed: 22010018
J Neurooncol. 2018 Dec;140(3):485-496
pubmed: 30377935
J Neurooncol. 2014 Dec;120(3):499-506
pubmed: 25115739
Cancer Invest. 1999;17(4):285-91; discussion 296-7
pubmed: 10225009
Jpn J Clin Oncol. 2015 Oct;45(10):906-13
pubmed: 26232448
Psychooncology. 2020 Mar;29(3):582-585
pubmed: 31733018
J Neurooncol. 2017 Jun;133(2):237-246
pubmed: 28540668
J Clin Oncol. 2015 Mar 20;33(9):1023-9
pubmed: 25667287
J Neurosurg. 1996 Jan;84(1):29-34
pubmed: 8613832
PLoS One. 2016 May 16;11(5):e0155431
pubmed: 27182821
Compr Psychiatry. 2000 Jan-Feb;41(1):63-9
pubmed: 10646621
Gen Hosp Psychiatry. 2013 Jul-Aug;35(4):359-65
pubmed: 23639186
Psychooncology. 2019 Jan;28(1):11-21
pubmed: 30280453
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Acta Oncol. 2019 May;58(5):745-752
pubmed: 30757955
Soc Work Health Care. 2008;47(4):455-78
pubmed: 19042496
Support Care Cancer. 2006 Dec;14(12):1205-12
pubmed: 16710652
Arch Phys Med Rehabil. 2003 Apr;84(4 Suppl 2):S29-34
pubmed: 12692769
Psychooncology. 2004 Apr;13(4):235-47
pubmed: 15054728
Qual Life Res. 2013 Dec;22(10):2685-91
pubmed: 23532341
J Natl Cancer Inst. 2011 Jan 5;103(1):61-76
pubmed: 21106962
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100
pubmed: 31675094
Neuro Oncol. 2009 Jun;11(3):330-9
pubmed: 19001097
J Occup Med Toxicol. 2015 Jul 19;10:24
pubmed: 26191076
Cancer. 2016 Jul 1;122(13):2110-6
pubmed: 27089045
Jpn J Clin Oncol. 2020 Sep 5;50(9):990-998
pubmed: 32484212
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Neuro Oncol. 2009 Feb;11(1):59-68
pubmed: 18713953
Neurosurg Focus. 2015 Jan;38(1):E6
pubmed: 25552286
Radiother Oncol. 2019 Aug;137:95-101
pubmed: 31082632
Eur J Oncol Nurs. 2017 Oct;30:113-119
pubmed: 29031307
Libyan J Med. 2021 Dec;16(1):1957199
pubmed: 34347581
BMC Cancer. 2020 Jan 15;20(1):35
pubmed: 31941467